Healthcare
Lucid Diagnostics Inc.(LUCD)
Live Price
Offline$1.03
+4.81% today
1Y Change
-15.28%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +8.3%
- EPS Growth
- +34.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lucid Diagnostics Inc. (LUCD) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $1.03 and down 15.3% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of +34.3%, a dividend yield of 0.0%. What stands out right now is revenue +8.3%, EPS +34.3%, free cash flow -103693.6% with operating margin -1054.8% and ROIC -135.1%. Valuation already assumes a fairly strong business story at price/sales 23.7. Stock Foundry combines LUCD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.3% vs +7.6% peer median
Operating Margin
Below sector median
-1054.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +8.3% and EPS at +34.3%, with operating margin around -1054.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | -2.0% | -4.1% |
2026 Mar 26, 2026 | -42.9% | -2.6% | -0.9% | -7.0% |
2025 Nov 12, 2025 | -66.7% | -3.6% | -8.1% | +2.7% |
Benchmark Edge
LUCD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LUCD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LUCD Max Drawdown
-35.58%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LUCD and SPY.
Company Overview
Lucid Diagnostics Inc.
NASDAQ Global Market
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
- Leadership
- Lishan Aklog
- IPO Date
- Oct 14, 2021
- Employees
- 72
- Street Address
- One Grand Central Place
- Mailing
- New York City, NY, 10165
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 949 4319
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 614.8
- Price/Sales
- 23.7
- Price/Book
- 10.2
Growth
- Revenue
- +8.3%
- EPS
- +34.3%
- Free Cash Flow
- -103693.6%
Profitability
- Gross Margin
- -55.6%
- Operating Margin
- -1054.8%
- Net Margin
- -1232.7%
- ROE
- -591.1%
- ROIC
- -135.1%
Balance Sheet
- Debt/Equity
- 2.36
- Current Ratio
- 1.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.